Jan 101 minYmmunobio Appoints Dr. Michel Janicot as Chief Development OfficerRIEHEN, SWITZERLAND, January 10, 2023 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of innovative...
Oct 19, 20221 minYmmunobio’s abstract accepted for poster presentation at SITC in Boston, November 2022RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM...
Oct 19, 20221 minYmmunobio selected by BIO-Europe to participate in its Start-up Spotlight SessionRIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM...